Pharma companies create $1bn fund to save antibiotic researchMore than 20 pharma companies including GlaxoSmithKline, Novartis and Pfizer have joined forces to create a $1 billion Share XPharma companies create $1bn fund to save antibiotic researchhttps://pharmaphorum.com/news/pharma-companies-create-1bn-fund-to-save-antibiotic-research/
Kymera Therapeutics begins potential $2bn R&D deal with SanofiUS biotech Kymera Therapeutics has begun a strategic collaboration with Sanofi to develop and market several drugs tackling immune-inflammatory disease, which Share XKymera Therapeutics begins potential $2bn R&D deal with Sanofihttps://pharmaphorum.com/news/kymera-therapeutics-begins-potential-2bn-rd-deal-with-sanofi/
Regeneron begins late-stage trial testing COVID-19 antibody cocktailRegeneron has begun a late-stage clinical trial testing its double “antibody cocktail” as a preventive treatment for COVID-19. Share XRegeneron begins late-stage trial testing COVID-19 antibody cocktailhttps://pharmaphorum.com/news/regeneron-begins-late-stage-trial-testing-covid-19-antibody-cocktail/
Digital techniques could ‘turbocharge’ R&D after COVID-19, say UK chemistry leadersThe UK’s Royal Society of Chemistry has called for digital techniques to be more widely used as part Share XDigital techniques could ‘turbocharge’ R&D after COVID-19, say UK chemistry leadershttps://pharmaphorum.com/news/digital-techniques-could-turbocharge-rd-after-covid-19-say-uk-chemistry-leaders/
UK trial begins testing second-wave COVID-19 drug from US biotech RidgebackThe AGILE programme, which is researching a second wave of COVID-19 therapies in the UK, has begun testing its first potential Share XUK trial begins testing second-wave COVID-19 drug from US biotech Ridgebackhttps://pharmaphorum.com/news/uk-trial-begins-testing-second-wave-covid-19-drug-from-us-biotech-ridgeback/
Idorsia on course to take on Eisai and Merck & Co after latest insomnia phase 3 trial winSwitzerland’s Idorsia says it is on course to file a potential next-generation insomnia drug around the end of this year after a Share XIdorsia on course to take on Eisai and Merck & Co after latest insomnia phase 3 trial winhttps://pharmaphorum.com/news/idorsia-on-course-to-take-on-eisai-and-merck-co-after-latest-insomnia-phase-3-trial-win/
Bharat Biotech begins trial of COVID-19 vaccine in India as cases mountBharat Biotech is to begin trials of a coronavirus vaccine in India as the country faces a rapidly growing Share XBharat Biotech begins trial of COVID-19 vaccine in India as cases mounthttps://pharmaphorum.com/news/bharat-biotech-begins-trial-of-covid-19-vaccine-in-india-as-cases-mount/
Merck KGaA’s ATR cancer drug cleared for further trials after phase 1 trial successMerck KGaA’s ATR inhibitor cancer drug has been cleared for further clinical trials after it showed encouraging activity in Share XMerck KGaA’s ATR cancer drug cleared for further trials after phase 1 trial successhttps://pharmaphorum.com/news/mercks-atr-cancer-drug-cleared-for-clinical-trials-after-phase-1-trial-success/
Sanofi and Translate Bio expand mRNA vaccine agreementSanofi’s Pasteur vaccines unit and Translate Bio have expanded a collaboration to develop mRNA-based vaccines across all infectious Share XSanofi and Translate Bio expand mRNA vaccine agreementhttps://pharmaphorum.com/news/sanofi-and-translate-bio-expand-mrna-vaccine-agreement/
